AVEO Pharmaceuticals (NASDAQ:AVEO) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.09, Fidelity Earnings reports. The company had revenue of $25.72 million for the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 242.26%.
AVEO Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $0.63. The stock had a trading volume of 30,179 shares, compared to its average volume of 2,667,067. AVEO Pharmaceuticals has a 12 month low of $0.47 and a 12 month high of $2.25. The firm’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.76. The firm has a market capitalization of $90.07 million, a PE ratio of -3.37 and a beta of 0.75. The company has a quick ratio of 2.21, a current ratio of 2.21 and a debt-to-equity ratio of 6.84.
AVEO has been the topic of a number of research analyst reports. ValuEngine downgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Piper Jaffray Companies cut their price target on shares of AVEO Pharmaceuticals from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $1.75 price target on shares of AVEO Pharmaceuticals in a report on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. AVEO Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $1.92.
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.